Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Primary Objective:

To evaluate objective response rate (ORR) in adult patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) who receive systemic treatment after at least 2 prior systemic therapies in the real-world setting according to Lugano classification of malignant lymphoma (Cheson, 2014) and as assessed by independent central review

Secondary Objectives:

To evaluate the following outcomes in adult patients with r/r DLBCL who are treated with currently available therapies in the real-world setting:

1. ORR according to Lugano classification and as assessed by treating physician evaluation

2. Complete Response (CR) rate according to Lugano classification and as assessed by:

   • Independent central review, and
   • Treating physician evaluation

3. Progression Free Survival (PFS) according to Lugano classification and as assessed by:

   • Independent central review, and
   • Treating physician evaluation

4. Overall Survival (OS)

5. Duration of response (DOR) according to Lugano classification and as assessed by

   • Independent central review and
   • Treating physician evaluation

6. Disease control rate (DCR) according to Lugano classification and as assessed by:

   • Independent central reviewed
   • Treating physician evaluation

7. Time to next treatment (TTNT)